Clopidogrel Bisulfate, also known as the brand name anticoagulant medication Plavix, continues to impress with its safety profile. A study released at the end of March 2013 revealed that patients set to undergo percutaneous coronary intervention could successfully continue their regimen of Clopidogrel during this time. Caution was extended from the study investigators, which took[…]
Clopidogrel Continues to Prove Its Safety and Efficacy
Antithrombotic, Blood Product, Drug Research & Development API, OTC and Compounding Product, Patent Expiration 2019 Tags: anticoagulantpercutaneous coronary interventionPlavix Jun 25, 2013
Prasugrel Is Key to Successful Angioplasties
Antithrombotic, Blood Product, Drug Research & Development API, FDA Approved 2009, Patent Expiration 2017 Tags: percutaneous coronary interventionPlavix Nov 20, 2012
Known as the brand name Effient, Prasugrel was approved by the FDA in July of 2009 as a blood thinning drug. Designed to be used to reduce the risk of blood clots from forming in patients who undergo angioplasty, which is a common procedure to unblock a clogged coronary artery, Prasugrel was studied in close[…]
Eptifibatide Continues to be Successful as an Antiplatelet Agent
Antithrombotic, Blood Product, Bulk Active Ingredient, Patent Expiration 2014, Patent Expiration 2015, TEVA API Tags: percutaneous coronary intervention Aug 06, 2012
Eptifibatide, CAS# 188627-80-7, is an antiplatelet agent. Also offered from LGM Pharma as a TEVA API (TAPI) product for compounding purposes, eptifibatide is also known by the brand name Integrilin, which is marketed by Merck. With Merck’s patent for Integrilin due to expire on November 11, 2014, and an additional patent revision due to expire[…]
